- Home
- ILAG vs OGEN Comparison
ILAG vs OGEN Comparison
Compare ILAG & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILAG
- OGEN
- Stock Information
- Founded
- ILAG 1981
- OGEN 1996
- Country
- ILAG Hong Kong
- OGEN United States
- Employees
- ILAG N/A
- OGEN N/A
- Industry
- ILAG Office Equipment/Supplies/Services
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- ILAG Consumer Discretionary
- OGEN Health Care
- Exchange
- ILAG Nasdaq
- OGEN Nasdaq
- Market Cap
- ILAG 9.4M
- OGEN 2.5M
- IPO Year
- ILAG 2022
- OGEN N/A
- Fundamental
- Price
- ILAG $0.49
- OGEN $1.50
- Analyst Decision
- ILAG
- OGEN
- Analyst Count
- ILAG 0
- OGEN 0
- Target Price
- ILAG N/A
- OGEN N/A
- AVG Volume (30 Days)
- ILAG 539.1K
- OGEN 1.1M
- Earning Date
- ILAG 07-15-2025
- OGEN 08-08-2025
- Dividend Yield
- ILAG N/A
- OGEN N/A
- EPS Growth
- ILAG N/A
- OGEN N/A
- EPS
- ILAG N/A
- OGEN N/A
- Revenue
- ILAG $7,506,551.00
- OGEN N/A
- Revenue This Year
- ILAG N/A
- OGEN N/A
- Revenue Next Year
- ILAG N/A
- OGEN N/A
- P/E Ratio
- ILAG N/A
- OGEN N/A
- Revenue Growth
- ILAG 16.50
- OGEN N/A
- 52 Week Low
- ILAG $0.34
- OGEN $1.35
- 52 Week High
- ILAG $1.35
- OGEN $75.60
- Technical
- Relative Strength Index (RSI)
- ILAG 50.81
- OGEN 27.35
- Support Level
- ILAG $0.48
- OGEN $1.35
- Resistance Level
- ILAG $0.56
- OGEN $4.19
- Average True Range (ATR)
- ILAG 0.09
- OGEN 0.43
- MACD
- ILAG -0.01
- OGEN -0.22
- Stochastic Oscillator
- ILAG 25.43
- OGEN 5.14
About ILAG Intelligent Living Application Group Inc.
Intelligent Living Application Group Inc focuses on designing and producing affordable, high-quality locksets and smart security systems. The company offers high-quality mechanical locksets and smart locks to its customers. Its product portfolio comprises various ODM indoor and outdoor locksets, such as deadbolts, entry locksets, privacy locksets, passage locksets, and storeroom locks, which are marketed through brands like Kambo and Bamberg. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.